Clinical Practice & Guidelines Flashcards

A 68-year-old patient on warfarin for atrial fibrillation presents with an INR of 9.2 but no active bleeding. According to current evidence-based guidelines, the most appropriate management is:

Answer: Hold warfarin, administer vitamin K 2.5–5 mg orally, and recheck INR in 24 hours

For supratherapeutic INR (>8) without significant bleeding, guidelines recommend holding warfarin and administering low-dose oral vitamin K (2.5–5 mg) to facilitate controlled reversal, with INR rechecked in 24 hours. 4F-PCC is reserved for major/life-threatening bleeding. Holding warfarin alone is insufficient at this INR level, and switching anticoagulants while the INR is critically elevated is contraindicated.

When applying the USPSTF framework in clinical practice, a Grade D recommendation means the clinician should:

Answer: Actively discourage the service because harms clearly outweigh benefits

USPSTF Grade D indicates the service has no net benefit or that harms outweigh benefits — clinicians should actively discourage its use. Grade C involves shared decision-making for select patients, Grade A/B recommends offering the service, and Grade I indicates insufficient evidence (not Grade D).

A 55-year-old type 2 diabetic patient with an eGFR of 38 mL/min/1.73 m² and HbA1c of 8.9% is already on metformin. Per current ADA/KDIGO guidelines, the next agent of choice that addresses both glycemic control and renal protection is:

Answer: An SGLT-2 inhibitor, provided eGFR is ≥20 and the patient has albuminuria

Current ADA/KDIGO 2022+ guidelines endorse SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) down to eGFR ≥20 mL/min specifically for cardiorenal protection, independent of glycemic benefit. The older threshold of eGFR ≥45 for glycemic efficacy no longer restricts renal-protective use. GLP-1 RAs are also recommended but are second-line when SGLT-2 inhibitors are tolerated. Sulfonylureas carry hypoglycemia risk in CKD; insulin is not the priority add-on here.

In the DHA regulatory framework, a healthcare professional who identifies a 'near miss' event (a safety incident that did not reach the patient) is legally obligated to:

Answer: Report it through the facility's incident reporting system; DHA mandates near-miss reporting under the Patient Safety Law

Under DHA's Patient Safety Law and its healthcare quality standards, near-miss events must be reported through the facility's designated incident reporting system — there is no minimum severity threshold exemption for near misses. Open disclosure to patients applies when harm has actually occurred, not near misses. Awaiting peer review before reporting creates unacceptable delays and violates mandatory reporting obligations.

A physician wants to enroll a cognitively intact, terminally ill patient in a clinical trial. The patient initially agrees but, after reading the consent form, states 'I'm not sure — my son usually makes my decisions.' According to ethical and legal standards for informed consent, the physician should:

Answer: Recognize that the patient retains decision-making capacity and obtain consent directly from the patient; family involvement is optional

A cognitively intact adult patient retains full legal and ethical decision-making capacity regardless of expressed preferences about family involvement. Deference to a family member is a cultural or personal preference, not a surrogate designation. The physician must obtain consent from the competent patient directly. Surrogate consent is only valid when the patient lacks capacity. Ethics committee referral is unwarranted here.

A 72-year-old patient with NYHA Class III heart failure with reduced ejection fraction (HFrEF, EF 30%) is already on maximally tolerated doses of an ACE inhibitor and carvedilol. His serum potassium is 4.8 mEq/L and eGFR is 42 mL/min. Per current ESC/ACC guidelines, the next evidence-based pharmacological step to reduce mortality is:

Answer: Replace the ACE inhibitor with an ARNI (sacubitril/valsartan) as the next mortality-reducing step

In HFrEF patients already on ACE inhibitor and beta-blocker, ESC 2021 and ACC/AHA 2022 guidelines recommend replacing the ACE inhibitor with an ARNI (sacubitril/valsartan) as it provides superior mortality benefit over ACE inhibitor alone (PARADIGM-HF). An aldosterone antagonist is also guideline-directed but ranks after ARNI upgrade in the algorithm. Ivabradine is for rate control adjunct, not the next mortality-reducing step. Hydralazine-nitrate is reserved for ACE/ARB/ARNI intolerance.